|
Chlorothiazide Ginseng Nuvaring Mercaptopurine |
Motion ibandronate study |
||
|
14. Paterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 5965. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246: 6774. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001; 88: 701 Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038 Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846854. Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996; 14: 25522559. Hultborn R, Gundersen S, Ryden S et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19: 33833392. Body J-J, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 13991405. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 11331137. Kohno N, Aogi K, Minami H et al. A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Proc. Soc Clin Oncol 2004; 23: 43 Abstr 668 ; . 24. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 14041411. Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat 2004; 14: 521. Major PP, Cook RJ, Chen B-L, Zheng M. Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Seventh Workshop on Bisphosphonates--From the Laboratory to the Patient. What is New in Bisphosphonates?, 24 26 March 2004, Davos, Switzerland, Poster 71. 27. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical end points. J Clin Oncol 2002; 25 Suppl 1 ; : S10S18. 28. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 11001120. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000; 56: 554562. Cook RJ, Lawless JF. Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics 1996; 52: 13111323. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2004; 21: 40424057. [Erratum in J Clin Oncol 22 2004 ; 1351]. 32. BONDRONATw [package insert] ibandronic acid prescribing information. Hertfordshire, UK: Roche Registration Limited 1996. Ibandronate naThe Chamber maintains a Member and Tourism rack in its lobby. Members have the opportunity to keep brochures in one of the slots to promote their business or service. "We often see people looking through the brochures while they're waiting for a meeting to start, " says Carolyn Golson, the Chamber' vice president of membership. Those interested in having their brochures appear in the rack should bring them to the Chamber, 451 Government St., and check in with Zandra Fenley at the front desk. Lesions. We compared the results with unenhanced CT scans and iodocholesterol scintigraphy. Skeletal complications. These agents have an increasing role in oncology, not only in the management of metastatic bone disease and skeletal complications, but also for the prevention of cancer treatment-induced bone loss. Additionally, there are increasing data to support the adjuvant use of bisphosphonates in breast cancer, and confirmatory studies are in progress. Nevertheless, several studies on oral therapy have been reported, and the role of the oral route is becoming clearer van Holten-Verzantvoort et al. 1987, 1993, Paterson et al. 1993, Kristensen et al. 1999, Tripathy et al. 2003 ; Table 1 ; . Paterson et al. 1993 ; randomised 173 patients with bone metastases from breast cancer to receive either clodronate capsules 1600 mg daily ; or placebo capsules of identical appearance in addition to appropriate anticancer treatment s ; . In the patients who received clodronate, there was a significant reduction in skeletal morbidity. Overall, the combined rate of all skeletal events was 219 per 100 patient years with clodronate compared with 305 on placebo. Most of the benefit could be attributed to the reduction in hypercalcaemic episodes 28 vs 52, P 0: 01 ; and the reduction in frequency of vertebral fractures 84 vs 124 per 100 patient years, P 0: 025 ; . There was no significant effect on non-vertebral fractures, radiotherapy requirements, changes in anti-tumour therapy or survival. Oral clodronate was generally well tolerated. These results indicated that oral clodronate can modify the course of skeletal disease in metastatic bone disease from breast cancer. However, at the 1600 mg dose the benefits seen are relatively small, and oral clodronate at this dose is not as effective as intravenous pamidronate in relieving pain or inhibiting bone Jagdev et al. 2001c ; . At higher doses 2400 mg ; , oral clodronate appears to be of similar efficacy to intravenous pamidronate at 60 mg every 3 weeks Diel et al. 1998a ; . However, comparison of this probably optimal dose of clodronate with full dose 90 mg ; pamidronate or zoledronic acid has not been performed. There are now no plans for oral pamidronate to be marketed. However, one of the first, randomised trials of bisphosphonate therapy in breast cancer was performed with enteric-coated oral pamidronate Van Holten-Verzantvoort et al. 1987 ; . One hundred and sixty-one women with bone metastases from breast cancer were randomised to standard anticancer treatment with or without oral pamidronate, initially at a dose of 600 mg day but subsequently reduced to 300 mg day because of poor gastrointestinal tolerability. An initial analysis reported a significant reduction in skeletal morbidity with a reduction in pathological fractures, episodes of severe bone pain and hypercalcaemia leading to a reduction in radiotherapy requirements and the need to change the underlying systemic treatment. However, a subsequent analysis revealed that most of this benefit was accrued in the patients who received the initial poorly tolerated dose of 600 mg pamidronate a day Van Holten-Verzantvoort et al. 1993 ; . Ibandronate is a highly potent amino-bisphosphonate that is licensed in Europe for the treatment of hypercal and ibritumomab. Intravenous ibandronateThe costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked ``advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ll Present address: Dept. of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam 1066 CX, The Netherlands. 11 To whom reprint requests should be addressed Lilly Research Laboratories, 1001 W. 10th St., Indianapolis, IN 46202 and idarubicin. Diffusion rates of indicators can significantly affect the fluorescence signals under some circumstances Winslow et al. 1994; Nowycky and Pinter, 1993 ; , because of the small size of parallel fiber presynaptic terminals, such considerations are unlikely to affect the fluorescence signals recorded here. For this reason we did not consider effects of differences in the diffusion coefficients of the indicators DIFFERENTIAL CRUSTAL MOTIONS IN FINLAND; PRELIMINARY EVIDENCE FROM APATITE FISSION TRACK THERMOCHRONOLOGY G.R. Murrell, P.A.M. Andriessen. Faculty of Earth Science, Vrije Universiteit, Amsterdam. murg geo.vu.nl The Finland part of the Baltic shield has remained largely inert throughout most of its post-Archaen ; history. However, areas surrounding this part of the shield have experienced several inter- and intra-plate tectonic events whose far field influences have been relatively subtle and the vertical crustal movements associated to them small. Thus, the unique low temperature sensitivity of Apatite Fission Track Thermochronology AFT ; means that it is an ideal tool to apply to the analysis of the geological evolution of the craton and the resolution of these far field processes. Preliminary results of the present study exhibit a range of apparent AFT ages from 27034 to 85070 Ma. There is also a spatial variance in the ages obtained, with ages in central southern Finland grouping in the vicinity of 350 to 450 Ma and the margins having either significantly lower 270 Ma ; or higher 850 Ma ; apparent AFT ages. Whether this is due to differential movements in the crust or other reasons remains to be confirmed. Length data have been obtained and samples with older apparent AFT ages reveal longer mean track lengths. Length measurements range from 11.111.68 m to 13.341.79 m with normally few long 14.5 m ; tracks. These results will have implications relating to a range of topics such as late Riphaen rifting and inversion of the Ladoga basin, the extent of a Caledonian foreland basin and North Atlantic margin formation. However, the results are preliminary and as more data comes available, more substantiated conclusions can be made and ifex. Fiscal 2005 was the first full year for the reformulated versions of the Chromagen and Niferex product lines acquired in April 2003. During fiscal 2005, revenues for the Niferex and Chromagen lines were .4 million, a 23% increase over fiscal 2004. Niferex and Chromagen continue to be the two leading branded oral anemia products in the United States with a combined total prescription market share of 11% in the latest quarter. Notably, in the last quarter, Chromagen and Niferex combined, captured 12% of new prescriptions. Cost of Ibandronate
COURSE DESCRIPTION This course is designed to provide students with the basic knowledge and skill needed to safely administer medications to clients with self-care needs. Content includes medication action, use, side effects, nursing implications, and client education for major drug groups. PERFORMANCE OUTCOMES: Provider of Care: 1. 2. 3. Define the terms used in the study of pharmacology. Identify and describe the principles of drug action including absorption, distribution, metabolism and excretion; drug-receptor interactions and categories of adverse effects. Demonstrate an understanding of common characteristics of drug classes: mechanisms of action, uses, side effects, examples of common drugs in each category and nursing responsibilities related to the administration of drugs in each class. Demonstrate the use of the nursing process in drug therapy. Demonstrate accuracy in calculating dosages of drugs and intravenous drip rates. Describe a teaching plan for a patient learning to use a new medication. Describe the alterations in drug effect on the elderly patient.
The following table lists the available netlist output format options. Protel Hierarchical EEsof Touchstone Algorex Protel Wirelist FutrureNet AppliconBRAVO Racal Redac Hilo AppliconLEAP Scicards Integraph Cadnetix Spice Mentor BoardStation 6 Calay Spice Hierarchical Multiwire Calay90 Star Semiconductor Orcad PLDnet Case Tango Orcad - PCB II CBDS Telesis PADS Ascii ComputerVision Vectron PCAD EDIF 2.0 VHDL PCAD NLT EDIF 2.0 Hierarchical Xilinx XNF Protel EEDesigner Protel 2 EEsof Libra and iloprost.
|
||
|
© 2009 |